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Abstract 
Background: Plasmodium vivax malaria is an important public health issue in the Amazon region, and it accounts for 
approximately 84 % of cases of the disease. Migration across the border between Brazil and French Guiana contrib-
utes to the maintenance of the disease. The aim of this study was to evaluate the therapeutic and parasitological 
responses of patients with P. vivax malaria treated with chloroquine and primaquine in the socio-environmental con-
text of cross-border interactions between Brazil and French Guiana. The factors controlled were diagnostic agreement, 
adherence, adjustment of primaquine doses for patient weight, and quality of the drugs used.
Methods: A prospective study was conducted in 2011 with 103 individuals aged 10–60 years with a positive diagno-
sis of P. vivax treated with chloroquine (10 mg base/kg on the first day, followed by 7.5 mg/kg on the second and third 
days) and primaquine for 7 days, who were followed for 28 days. The primaquine doses were adjusted for the patients’ 
weight. A number of factors were determined: epidemiological characteristics, origin of patients, signs and symptoms, 
initial parasitaemia and parasitaemia clearance time, blood concentrations of chloroquine and primaquine, quality of 
anti-malarial drugs and diagnostic agreement.
Results: Ninety-five patients were followed for 28 days. There was a 100 % agreement in microscopic diagnosis 
between field laboratory and reference centre. The adhesion to the treatment was 100 %. Of these patients, 32.6 % 
received a weight-adjusted dose of primaquine. The chloroquine and primaquine tablets were consistent with the 
optimal quality limits for human consumption. The investigated patients achieved optimal blood exposure to anti-
malarial drugs. The parasitological and therapeutic response was adequate in 99.0 % of cases.
Conclusions: In the municipality of Oiapoque, the therapeutic regime used for the treatment of P. vivax malaria 
using chloroquine combined with primaquine remains effective, when external factors are controlled, such as the 
quality of anti-malarial drugs, the adhesion to the treatment prescribed, the correct diagnostic and the adjustment of 
primaquine dose for patient body weight.
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Background
Plasmodium vivax malaria is an important public 
health issue in the Amazon region, and it accounts for 
approximately 84  % of malaria cases [1]. Environmental 
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characteristics, such as climate and hydrography, which 
are associated with movement of the Anopheles vector, 
contribute to maintenance of transmission of this dis-
ease in this area, which is considered as hypo- to meso-
endemic, unstable and with annual seasonal fluctuations 
[1, 2]. The disease does not occur uniformly across the 
region, as locations with different levels of transmis-
sion have been observed [1, 2]. In the municipality of 
Oiapoque, which is located in the state of Amapá-AP in 
the far northern Brazilian Amazon and bordering French 
Guiana, the disease shows peculiar characteristics due to 
frequent cross-border migration. The municipality is at 
high risk of transmission, with approximately 5000 cases 
reported annually and a predominance of infections with 
P. vivax, which represent 82 % of cases [1].
Early diagnosis and timely and appropriate treatment 
play a central role in disease control because both pre-
vent the occurrence of severe cases and consequently 
death as well as in eliminating the sources of infection 
for mosquitoes [3, 4]. The treatment of choice for P. vivax 
consists of chloroquine for 3  days combined with pri-
maquine diphosphate for 7 days, and the second choice 
is primaquine for 14 days with the same dose of chloro-
quine [3, 4]. In Brazil, the national malaria control pro-
gramme (Programa Nacional de Controle da Malária 
(PNCM)) provides guidelines for treatment and distrib-
ute anti-malarial drugs with no costs [4].
The variability of Plasmodium response to anti-malar-
ial drugs limits therapeutic success. Parasites that appear 
at diagnosis (D0) and are not detected on the 28th day 
are considered sensitive [3]. Treatment failure may result 
from resistance of P. vivax strains circulating in a given 
endemic area in addition to other factors [5–7]. Factors 
intrinsic to the host, the parasite and the anti-malarial 
drugs, as well as their interactions, contribute to treat-
ment failure. Such factors include intra- and inter-racial 
variability of the pharmacokinetic profiles of anti-malar-
ial drugs, quality of anti-malarial drugs, accuracy in iden-
tifying the Plasmodium species, and exposure to low 
concentrations of anti-malarial drugs resulting from low 
quality of drugs, poor adherence to the prescribed regi-
men, vomiting and others gastrointestinal disorders, and 
finally, the adjustment of primaquine dose as a function 
of patient body weight [6–9].
Several studies have evaluated the efficacy of chloro-
quine plus primaquine for P. vivax in Brazil and in other 
countries of South America; however, the use of non-
standardized protocols makes it difficult to compare the 
percentages of treatment failure [10–15]. Additionally, 
few studies have assessed in an integrated way the factors 
that are responsible for treatment failure but not directly 
related to resistance of the parasite or the host immune 
response [16–18]. Thus, this study aimed to evaluate the 
therapeutic and parasitological response of patients with 
vivax malaria treated with chloroquine and primaquine 
in the socio-environmental context of cross-border inter-
actions between Brazil and French Guiana by considering 
adherence, concordance of diagnosis, primaquine dose 




The study was conducted in the municipality of 
Oiapoque-AP in the Amazon region of far northern Bra-
zil. Oiapoque shares an international border with French 
Guiana. Oiapoque is situed at sea level and has an area of 
22.625 Km2. The annual average humidity ranges from 75 
to 85  %. There are two seasons: rainy season (January–
June), with a rainfall average of 1800 mm3 and dry season 
(July–December), with a rainfall average of 500 mm3. The 
annual average temperature ranges from 23 to 32 °C. The 
resident population is 20,509 inhabitants and fluctuates 
by 10,000–12,000 individuals. The annual parasite index 
(API) was 246/1000 population in 2011 [01].
Patients
Individuals of both genders aged 16–60  years who 
spontaneously searched for public health care services 
in Oiapoque with signs and symptoms suggestive of 
malaria, from August to December 2011, and with a posi-
tive thick blood smear for vivax malaria were included in 
the study. Individuals with chronic and infectious con-
comitant disease, patients with mixed, severe or com-
plicated malaria, pregnant women, indigenous people, 
patients with reports of prior adverse reactions to the 
drugs and those who disagreed or did not sign the con-
sent form were excluded.
Quality control of chloroquine diphosphate 
and primaquine diphosphate tablets
The drugs used were supplied by the Coordination of 
Pharmaceutical Assistance of Amapá (Coordenadoria de 
Assistência Farmacêutica do Amapá). Prior to use, the 
validity, concentration and lots of all drugs were care-
fully checked. Moreover, physicochemical analyses were 
performed prior to use, which consisted of determining 
the weight of the tablets according to the general meth-
ods described in the Brazilian Pharmacopoeia [19]. Next, 
dissolution tests and determination of the active ingredi-
ent content were performed as described for each drug 
in the Brazilian Pharmacopoeia [20]. In the dissolution 
test, a tolerance of 70 % of chloroquine diphosphate and 
80 % of primaquine diphosphate (relative to the amount 
declared on the label) dissolving in 45 min was adopted. 
The values obtained in the test for determining the active 
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ingredient content of the tablets were required to be 
between 93.0 and 107.0 % of the labelled value.
Clinical assessment
Clinical assessments were carried out after confirma-
tion of vivax malaria, before treatment with anti-malar-
ials (D0) and after one, three, seven, 14, 21, and 28 days. 
The typical signs and symptoms of malaria as well as 
non-specific symptoms were classified as ‘present’ or 
‘absent’ [3, 4]. Patients included in the study were care-
fully informed of the need for a replacement dose in case 
of vomiting less than 30 min after ingestion of the drug, 
and in case of heavy and prolonged diarrhoea, they were 
asked to immediately contact the healthcare team.
Therapeutic regime
The first-line regimen used to treat vivax malaria con-
sisted of chloroquine diphosphate (Farmaguinhos Labo-
ratory –Fundação Oswaldo Cruz/Rio de Janeiro, Brazil) 
at doses of 10  mg base/kg on the first day followed by 
7.5  mg/kg on the second and third days, corresponding 
to a total dose of 25 mg/kg, combined with primaquine 
diphosphate (Farmaguinhos Laboratory – Fundação 
Oswaldo Cruz/Rio de Janeiro, Brazil) at a dose of 0.50 kg 
base/kg for 7  days, corresponding to a total dose of 
3.0–3.5 mg/kg. The dose of primaquine was adjusted for 
weight for patients weighing 70 kg or more as shown in 
Table  1 [3, 4]. The patients were weighed on the day of 
inclusion in the study using a previously calibrated bal-
ance with digital scale. A patient who exhibited treatment 
failure with chloroquine  +  primaquine received a regi-
men of weekly chloroquine for 12 weeks [3, 4].
Adherence to treatment
The adherence by patients to treatment was evaluated 
during follow-up clinical interviews, as well as by pill 
counting performed daily at home of patients. Subse-
quently, these values were compared with blood anti-
malarial drug concentrations [9, 21, 22].
Parasite density and parasitaemia clearance time
The thick smear was stained with Giemsa following Walk-
er’s method and examined under a light microscope. Para-
sitaemia was determined by counting the parasites in 100 
microscopic fields (750 times), and this value was mul-
tiplied by five, with the result expressed as parasites per 
cubic millimetre of blood. Smears were considered nega-
tive (i.e., absence of parasitaemia) when, after examining 
at least 200 microscopic fields, asexual forms of P. vivax 
were not found. Three levels of parasitaemia were defined: 
low, intermediate, and high, which corresponded to up to 
15,000, 15,001–60,000, and equal to or greater than 60,001 
parasites per mm3 of blood, respectively. The parasitaemia 
for inclusion in the study ranged from 200 to 100,000 par-
asite per mm3 of blood. The parasitaemia clearance time 
(PCT) of the patients was checked every 24 h using thick-
smear slides on days 1, 2, 3, 4 5, and 7. Values are expressed 
as the means and standard deviation [23, 24].
Diagnostic agreement
All positive slides were reviewed in the Central Labora-
tory of Public Health of Amapá (Laboratório Central de 
Saúde Pública do Amapá—LACEN-Amapá) reference 
laboratory.
Blood samples
Blood samples (approximate volume of 20 μL) were col-
lected during clinical assessments using finger-prick 
lancets. Samples were then mounted on glass slides to 
obtain thick blood smears [25]. For the dosage of the anti-
malarials, venous blood samples were collected in EDTA 
anticoagulant on days 0, 3, 14, 21, and 28, applied to filter 
paper (Whatman 17Chr,® Pennsylvania, USA), and dried 
at room temperature for 4  h. Then, the filter paper was 
placed in a paper envelope.
Determination of blood concentrations of chloroquine 
and primaquine
Chloroquine and primaquine were measured in order 
to assess the adherence. A reverse-phase high-per-
formance liquid chromatography system was used 
for the measurement of both drugs. The chromato-
graphic conditions for determination of primaquine 
were as follows: UV detection: 254 nm; flow rate: 1 mL/
min; column: RP-8.15  cm, 5  μm and 4.6  mm internal 
diameter (Waters, Saint Quentin-en-Yvelines, France); 
mobile phase: acetonitrile:methanol:water (30:26:95, 
v/v); pH 5; injection volume: 50 mL. The validated ana-
lytical procedure for the determination of primaquine 
concentrations showed that the method was linear 
from 10 to 900  ng/mL. The mean intra- and inter-day 
coefficients of variation were 8.3 and 12.1  %, respec-
tively. The limit of detection was 5 ng/mL and the limit 
of quantification was 10  ng/mL. The mean retention 
Table 1 Adjustment of  primaquine dose and  time 
of administration for patients weighing more than 70 kg
Source: Ministry of Health (Ministério da Saúde), Brazil [4]
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time of primaquine was 8.8  min and of quinidine 
(internal standard) was 7.0 min. The mean recovery of 
primaquine was 90.3 %. The stability of samples supple-
mented with primaquine was 120 days under the condi-
tions described above [26].
For chloroquine, the chromatographic conditions were 
as follows: column: C-8, Xterra 4.6  ×  150  mm in size, 
5-μm particles, reverse phase RP18; pre-column: Xterra, 
RP18 3.9 × 20 mm, 5-μm particles; mobile phase: 40 % 
acetonitrile, 60 % (1 % triethylamine in water); pH 10.5, 
flow rate: 1.2 mL/min; UV detection: 333 nm; excitation: 
330 nm; temperature: 25 °C; injection volume: 50 μL. The 
mean retention time for chloroquine was 20.0  min and 
for quinine (internal standard) was 6.0  min. The limit 
of detection was 25  ng/mL and the limit of quantifica-
tion was 38  ng/mL. The method was linear from 38 to 
250 ng/mL. The mean recovery was 87 %. The intra- and 
inter-day coefficients of variation were 10.5 and 13  %, 
respectively. The stability of samples supplemented with 
chloroquine was 90 days [27].
Classification of parasitological and therapeutic responses
The World Health Organization classification criteria for 
parasitological response in areas with intense transmis-
sion was adopted, with sensitive (S) or resistant types 
I, II and III [3]. Parasitological cure was defined as the 
disappearance of asexual parasitaemia after beginning 
a specific treatment and its absence during the follow-
ing 28 days, and treatment failure was evidenced by the 
recurrence of parasitaemia during this period. Resistance 
to chloroquine was identified based on the recurrence of 
parasitaemia in the presence of minimum effective con-
centrations of chloroquine (CQ) and desethylchloroquine 
(DCQ) of 100  ng/mL in whole blood during follow-up, 
regardless of the source of recurrence, i.e., resurgence, re-
infections and relapses [6, 7].
Sample size
The sample size was based on the World Health Organi-
zation protocol for studies of the efficacy of anti-malarial 
drugs in the Americas, specifically of the efficacy of chlo-
roquine in the treatment of vivax malaria. A minimum 
of 81 patients was required, but the study included 103 
patients, with 95 who were fully monitored [3, 28].
Statistical analysis
Samples are expressed as the means (SD) and as median 
and range when required. The Fisher’s exact, Chi square 
and G tests were used to compare the variables: gen-
der, age, origin of cases, and signs and symptoms of the 
disease. The correlation between parasitaemia and the 
presence of signs and symptoms of infection was deter-
mined by the Spearman’s correlation coefficient (s). The 
Mann–Whitney test was used to compare parasitaemia 
clearance times. The accepted level of significance was 
5 %.
Ethics
The study was approved by the Research Ethics Commit-
tee of the SEAMA School under protocol number CEP/
SEAMA No. 079/08 of 11/27/2008 as part of the main 
project. Candidate participants were only included in the 
study after receiving clarification and providing written 
agreement to participate in the study.
Results
A total of 103 patients with laboratory diagnosis of vivax 
malaria were initially included in the study. Of these, 95 
completed the follow-up. Six participants were excluded 
due to loss to follow-up, because they went away of 
Oiapoque. Another two patients were excluded due to 
concurrent infections with Plasmodium falciparum, 
which was diagnosed during the first week of follow-up.
Epidemiological characteristics and origin of cases
The majority of patients were males (67 %). The mean age 
was 30 (±12) years, ranging from 16 to 60 years. The age 
group most affected by the disease was 20–29 years fol-
lowed by 30–39 years for both genders. A total of 19 % of 
cases corresponded to primary infection. Reports of pre-
vious infection were divided into one, two and more than 
four, corresponding to 2, 15 and 64  % of cases, respec-
tively. Autochthonous cases in Oiapoque represented 
69 % (p = 0.0002). Of cases originating in French Guiana, 
the illegal gold mining site of ‘Sikini’ was the most com-
monly cited with 21.9 % of cases (p < 0.0001).
Quality of chloroquine diphosphate and primaquine 
diphosphate tablets
The mean weight of the chloroquine diphosphate tab-
lets was 412 mg, with a unit-to-unit variation of −2.50 to 
3.30 %, while the mean weight of the primaquine diphos-
phate tablets was 128 mg, with a unit-to-unit variation of 
−5.30 to 4.25  %. No tablet unit was outside the weight 
range recommended in the Brazilian Pharmacopoeia, i.e., 
between −7.5 and 7.5 %. The dissolution test for chloro-
quine diphosphate tablets showed a release rate of 78 % 
(± 2.4) in 45 min, which is above the upper limit of 70 %. 
The primaquine diphosphate tablets exhibited a release 
rate of 85 % (±3.2) in 45 min, which was also above the 
minimal tolerance value of 80 %. The mean chloroquine 
diphosphate content in the tablets was 98.31 (2.11)  %, 
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ranging from 96.33 to 103.45  % of the labelled value. 
The mean primaquine diphosphate content in the tab-
lets was 99.87 (2.28) %, ranging from 98.12 to 101.13 %, 
i.e., within the acceptable range of 93.0–107.0  % of the 
labelled value.
Clinical findings
Several clinical symptoms were reported, includ-
ing fever (88  %), chills and headache (86  %), sweat-
ing (83  %), myalgia (43  %), and nausea (56  %). Despite 
fever being the most frequent clinical manifestation, it 
was not the initial complaint in 12 % of patients. Other 
symptoms, such as headache, myalgia and nausea were 
initially mentioned. The classic triad of malarial symp-
toms (fever, chills and headache) was reported in 46.7 % 
of cases. There was a significant correlation between 
parasitaemia and the presence of signs and symptoms of 
infection (p < 0.0001).
Dose adjustment of primaquine
The dose of primaquine was adjusted in 32.6  % of 
patients weighing 70  kg or more by adding two 15-mg 
tablets on each day, which is equivalent to 0.30  mg/
day. In this group, the total dose of primaquine ranged 
from 240 to 304 mg. The duration of administration was 
increased from 8 to 10 days to reach the total dose of pri-
maquine. The adjustment of doses did not alter blood 
concentrations of primaquine (Z = 1.5195, p = 0.0643). 
It is noteworthy that the relapsed patient did not require 
adjustment, as the patient weighed 55 kg.
Adherence to treatment
The pill count during the clinical assessments carried out 
during treatment to evaluate the adherence indicated a 
rate of 100  % adherence to treatment. This finding was 
corroborated by anti-malarial blood concentrations on 
follow-up assessment days.
Parasite density and parasitaemia clearance time
The geometric mean of parasitaemia was 1168 (±3.32) 
parasites/mm3 on D0. The parasitaemia decreased begin-
ning on D2 and remained negative until D28 (Table  2), 
except for one patient who had 400 parasites/mm3 on 
D28. The parasitaemia on D0 was low in 90 patients and 
intermediate in five patients (p < 0.0001). There were no 
cases of high parasitaemia.
The parasitaemia clearance time ranged from 48 to 
120  h. All patients were negative for parasitaemia dur-
ing the first week of treatment. Of these, 80 % were nega-
tive on D3 and the rest during the first week (D0–D7). 
Patients with an intermediate parasite density showed a 
longer parasitaemia clearance time compared to those 
with low parasite density (p = 0.0284).
Diagnostic agreement
Comparison of the diagnoses by thick smears performed 
in Oiapoque and during the quality control process by 
LACEN-AP indicated 100 % diagnostic agreement.
Blood concentrations of chloroquine and primaquine
Blood concentrations of chloroquine and primaquine 
during follow-up visits are shown in Table 3. The whole 
blood chloroquine concentrations during follow-up 
were greater than 100  ng/mL, including the patient 
who relapsed with positive parasitaemia on day 28 of 
follow-up.
Classification of parasitological and therapeutic responses
The therapeutic response was considered appropriate in 
94 patients (99 %) with complete disappearance of symp-
toms and clearance of parasites, which was classified as 
sensitive (S). One participant (1.0 %) had late treatment 
failure, with a parasitological response classified as resist-
ance type RI (Table  4). This patient was treated with 
chloroquine for 12  weeks taking care to ensure correct 
Table 2 Parasite density in patients with Plasmodium vivax malaria in Oiapoque/AP
Source: Primary data, 2013
* Patients who had positive parasitaemia on D3
** Patient who had positive parasitaemia on D28
Parasites: asexual form Days of follow-up
D0 D3 D7 D14 D21 D28
Geometric mean (V/mm3) 1167.86 40.33 0 0 0 0
Geometric standard deviation ±3.32 ±4.07 0 0 0 0
Minimum (parasites/mm3) 200 5 0 0 0 0
Maximum (parasites/mm3) 36000 350 0 0 0 0
Relapsed patient 3000 350 0 0 0 400
Number of patients 95 19* 0 0 0 01**
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patient adherence to conventional treatment, following 
the recommendation of Brazilian Health Office.
Discussion
Malaria on the French Guiana-Brazilian border has been 
linked to high population mobility towards the French 
gold mines, where its incidence is high [29]. Although 
most cases are autochthonous to Oiapoque, intense 
cross-border migration precludes confirmation of the 
exact location of infection. Indeed, the predominance 
of cases in adult males in the economically active age 
groups show the importance of illegal gold mining in 
areas of high occurrence of the disease in French Guiana, 
such as the Sikini gold mine.
Low to moderate parasitaemia is common in P. vivax 
infections in the Brazilian Amazon and may have been 
responsible for the classic triad of the disease being diag-
nosed in only half of patients, despite reports of severe 
cases with low parasitaemia and the influence of host 
immune status, comorbidities, strain virulence, and oth-
ers in the initial clinical manifestations. In addition, the 
parasitaemia clearance time observed in the study resem-
bled that of other endemic areas in which the sensitivity 
of P. vivax to chloroquine is maintained [12–15, 30].
The mean blood concentrations of chloroquine during 
follow-up visits corroborate the findings in other popula-
tion groups, including the Brazilian Amazon, under the 
same treatment regimen [15, 31, 32]. Similarly, the mean 
blood concentrations of primaquine during treatment 
resembled those previously reported in Indian patients 
with vivax malaria under the same therapeutic regimen 
[33].
The adequate parasitological response at the end of 
clinical-laboratory follow-up showed the therapeutic effi-
cacy of the standard treatment in 99 % of cases, confirm-
ing previous findings in patients treated with the same 
therapeutic regimen in Belém, in the Brazilian state of 
Para [34]. However, the data show only high effectiveness 
of chloroquine against P. vivax blood stages but do not 
ensure a radical cure, as in Brazil relapse can occur up 
to 6  months following the completion of treatment [35, 
36]. In addition, the adequate parasitological response of 
patients with recurrent vivax malaria corroborates the 
efficacy of treatment. High rates of recurrent infection 
are commonly reported in areas of endemic transmission 
of the disease and have been associated with a new infec-
tion or relapse of hypnozoites. Studies in the Brazilian 
Amazon have reported decreased efficacy of these drugs 
for the treatment of P. vivax [10, 12, 15, 35, 36]. However, 
there are several difficulties to follows the standardized 
guidelines proposed by WHO for evaluation of the effi-
cacy of anti-malarial drugs in Brazilian Amazon basin 
either by its continental dimensions or by the larger bor-
der with other Amazon countries with their own police of 
diagnosis and treatment of the disease [2, 9–12, 15, 16]. 
These limitations impose methodological differences, 
Table 3 Blood concentrations of chloroquine diphosphate and primaquine diphosphate in ng/mL
Source: Primary Data, 2013
ND Not detected
Description Chloroquine diphosphate in ng/mL Primaquine diphosphate in ng/mL
Days of follow up D0 D1 D3 D28 D0 D1 D3 D28
Number of patients 95 95 95 1 95 95 95 1
Mean level ND 461.1 119.6 – ND 32.47 50.8 –
Standard deviation ND 224.9 495.9 – ND 17.63 22.1 –
Minimum level ND 209 286 – ND 13.6 18.0 –
Maximum level ND 992 2213 – ND 99.5 98.3 –
Relapsed patient ND 324 1120 210 ND 58.9 26.2 ND
Table 4 Classification of parasitological and therapeutic responses
Primary source
ACR adequate clinical response, LTF late treatment failure, ETF early treatment failure, S sensitive, RI resistance type I, RII resistance type II, RIII resistance type III, 
N absolute number
Clinical response ACR LTF ETF
Parasitological response S RI RII RIII Total
Regimen Nº  % Nº % Nº % Nº %
Chloroquine + primaquine 94 99.0 01 1.0 – – – – 95
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such as the length of treatment, dose adjustments of 
primaquine as a function of patient weight, dose admin-
istered, and the no assessment of anti-malarial drugs 
exposure, hinder comparisons of studies of the therapeu-
tic efficacy of the chloroquine and primaquine combi-
nation against P. vivax [2, 9–12, 15, 16]. As an example, 
epidemiological records of the Malaria Epidemiological 
Surveillance Information System (Sistema de Informação 
de Vigilância Epidemiológica—SIVEP-Malária)/MS in 
Oiapoque indicated that 14.2 and 13.5 % of cure verifica-
tion slides were positive in 2009 and 2010, respectively. 
However, one should consider that the examination in 
this study was conducted on day 28 after beginning treat-
ment, as opposed to the 60  days recommended by the 
Ministry of Health after treatment for P. vivax.
The control of factors responsible by treatment fail-
ures in vivax malaria evaluated in the current study, such 
as the adjustment of the dose of primaquine for patient 
weight, the intrinsic quality of the drugs, and the adher-
ence of all patients to the prescribed treatment assessed 
through interviews, pill counts and confirmation of drug 
exposure by the concentrations of anti-malarial drugs in 
blood may have contributed to the high effectiveness of 
the standard treatment. In addition, the efficiency of dis-
ease control policies in Brazil, based on early and correct 
diagnosis, as well as in the timely and appropriate treat-
ment of cases, may have also contributed to these find-
ings, which was corroborated by the agreement of thick 
blood smear diagnoses between different treatment cen-
tres, as well as by the absence of anti-malarial drugs in 
pre-dose samples [4].
Late treatment failure in one patient could be classified 
as resistance type RI. The plasma concentration of chlo-
roquine at D28 was greater than 100  ng/mL, indicating 
adequate drug exposure as well as the presence of blood 
strains of P. vivax at concentrations above the minimum 
inhibitory concentration for chloroquine-sensitive strains. 
The treatment failure could be explained by the fact that 
there are different parasite genotypes circulating in the 
region [6, 7, 25, 37]. In addition, it is important to highlight 
that the only patient with treatment failure shows concen-
trations of primaquine on day 3 approximately 50 % lower 
than on day 1, while in the remaining levels on day 3 were 
higher than in day 1. This finding could be useful to explain 
the treatment failure see in the current study.
Conclusion
In the municipality of Oiapoque the treatment regimen 
of chloroquine combined with primaquine used for the 
treatment of vivax malaria remains effective. In addition, 
circulating P. vivax isolates have no significant resistance 
profile to the currently recommended treatment. The 
control over external factors, such as the dose adjustment 
of primaquine based on the weight of the patient, the 
quality of anti-malarial drugs and adherence to treat-
ment, contributed to the high effectiveness of the stand-
ard treatment found in the study.
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